|
Title
|
|
|
|
Maintained intentional weight loss reduces cardiovascular outcomes : results from the Sibutramine Cardiovascular OUTcomes (SCOUT) Trial
|
|
|
Author
|
|
|
|
|
|
|
Institution/Organisation
|
|
|
|
SCOUT Investigators
|
|
|
Abstract
|
|
|
|
| Aim: The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality. The relationship between 12-month weight loss and subsequent cardiovascular outcomes is explored. Methods: Overweight/ obese subjects (N = 10 744), = 55 years with cardiovascular disease and/ or type 2 diabetes mellitus, received sibutramine plus weight management during a 6-week Lead-in Period before randomization to continue sibutramine (N = 4906) or to receive placebo (N = 4898). The primary endpoint was the time from randomization to first occurrence of a primary outcome event (non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death). Results: For the total population, mean weight change during Lead-in Period (sibutramine) was -2.54 kg. Post-randomization, mean total weight change to Month 12 was -4.18 kg (sibutramine) or -1.87 kg (placebo). Degree of weight loss during Lead-in Period or through Month 12 was associated with a progressive reduction in risk for the total population in primary outcome events and cardiovascular mortality over the 5-year assessment. Although more events occurred in the randomized sibutramine group, on an average, a modest weight loss of approximately 3 kg achieved in the Lead-in Period appeared to offset this increased event rate. Moderate weight loss (3-10 kg) reduced cardiovascular deaths in those with severe, moderate or mild cardiovascular disease. Conclusions: Modest weight loss over short-term (6 weeks) and longer-term (6-12 months) periods is associated with reduction in subsequent cardiovascular mortality for the following 4-5 years even in those with pre-existing cardiovascular disease. While the sibutramine group experienced more primary outcome events than the placebo group, greater weight loss reduced overall risk of these occurring in both groups. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Diabetes, obesity & metabolism. - Oxford, 1999, currens
|
|
|
Publication
|
|
|
|
Oxford
:
Blackwell
,
2012
|
|
|
ISSN
|
|
|
|
1462-8902
[print]
1463-1326
[online]
|
|
|
DOI
|
|
|
|
10.1111/J.1463-1326.2011.01554.X
|
|
|
Volume/pages
|
|
|
|
14
:6
(2012)
, p. 523-530
|
|
|
ISI
|
|
|
|
000303049800006
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|